It has been suggested that plasma sTREM2 levels in MASH patients correlate with ALT and AST, are associated with MASH risk status, and may serve as a reasonable biomarker for identifying patients eligible for clinical trials in MASH (80, 81). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.